B4GALNT2抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P09345(B4GALNT2 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

**Background of B4GALNT2 Antibody**

The B4GALNT2 (β-1.4-N-acetylgalactosaminyltransferase 2) gene encodes an enzyme involved in glycosylation, specifically catalyzing the transfer of N-acetylgalactosamine (GalNAc) to terminal galactose residues in glycoconjugates. This enzyme plays a key role in synthesizing the Sd^a antigen (GalNAcβ1-4[SAα2-3]Gal), a carbohydrate structure expressed on erythrocytes, intestinal tissues, and secreted glycoproteins. B4GALNT2's expression is tissue-specific, with high activity in the gastrointestinal tract, kidneys, and placenta.

Antibodies targeting B4GALNT2 are valuable tools for studying its biological roles and dysregulation in diseases. Research links B4GALNT2 to cancer, as altered expression is observed in colorectal tumors, potentially influencing cell adhesion and signaling. It also interacts with pathogens; some bacteria exploit Sd^a antigens for adhesion, implicating the enzyme in host-microbe interactions. Additionally, B4GALNT2 mutations are associated with rare genetic disorders, such as Tn syndrome-like phenotypes, affecting glycosylation pathways.

B4GALNT2 antibodies enable detection of protein expression via techniques like Western blotting, immunohistochemistry, and flow cytometry. They aid in exploring its regulatory mechanisms, substrate specificity, and potential as a diagnostic or therapeutic target. Recent studies also investigate its role in immune modulation, particularly in inflammatory bowel disease (IBD) and autoimmune conditions. Understanding B4GALNT2's functions through antibody-based research continues to uncover its significance in glycobiology and disease pathogenesis.